Journal of Oncology Pharmacy Practice最新文献

{"title":"Diagnosis and management of immune checkpoint inhibitor-associated adrenal insufficiency: A single-institution experience.","authors":"Brooke Jennings, Andrea Arenz, Susan M Frankki, Aiman Riaz","doi":"10.1177/10781552251332284","DOIUrl":"10.1177/10781552251332284","url":null,"abstract":"<p><p>BackgroundImmune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of various malignancies. Unfortunately, ICI therapy has been associated with multiple immune related adverse events (irAEs) resulting in organ damage. One rare, but potentially devastating side effect, is adrenal insufficiency.MethodsA retrospective analysis of all patients receiving anti-PD-1/PD-L1 or anti-CTLA-4 therapy at Gundersen Health System from 2011 to 2023 was conducted.ResultsPatients (n = 684) receiving anti-PD-1/anti-PD-L1/anti-CTLA-4 therapy at Gundersen Health System were included in our retrospective analysis. There were eleven (1.6%) patients that were diagnosed with an adrenal irAE after beginning immunotherapy. The median days from first treatment to diagnosis of irAE was 304 days. Most common symptoms at the time of onset included fatigue (82%) and syncope (36%). Five patients (45%) required treatment delay or cessation and eight (73%) patients were referred to endocrinology after original diagnosis.DiscussionDetection of adrenal insufficiency secondary to immunotherapy requires a degree of high suspicion. Given the potential significant morbidity and mortality associated with adrenalitis/adrenal insufficiency, prompt diagnosis is of the utmost importance. Liberal use of early morning/8 am cortisol screening should be implemented as a standard part of clinical work up in acute onset of fatigue, hypotension, fever, weakness, weight loss, dehydration, oral intolerance, gastrointestinal upset, hyponatremia, and hyperkalemia. Immunotherapy related adrenal insufficiency is a rare complication, with most cases being secondary adrenal insufficiency. Multidisciplinary care with oncology and endocrinology is an important aspect of comprehensive management.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1235-1240"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of pegfilgrastim in preventing febrile neutropenia during DCF chemotherapy for esophageal cancer: A systematic review and meta-analysis.","authors":"Khaled Hemdan, Rana Mohamed El Tabakh, Ziad W Elmezayen, Amr Mahmoud Yousef, Ahmed Hussein, Ali M Elghareab, Mazen Momtaz Shehata, Alaa Abdelaziz Ellethey, Ahmed Oun","doi":"10.1177/10781552261416090","DOIUrl":"10.1177/10781552261416090","url":null,"abstract":"<p><p>BackgroundEsophageal cancer remains a leading cause of cancer-related mortality worldwide, with docetaxel, cisplatin, and fluorouracil (DCF) chemotherapy being a standard treatment option for locally advanced disease. However, DCF is associated with a high incidence of febrile neutropenia (FN), a serious complication that can lead to treatment delays, hospitalizations, and increased morbidity. Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is recommended for FN prevention, but its efficacy in esophageal cancer patients receiving DCF chemotherapy remains unclear.MethodsA systematic literature search of PubMed, Cochrane Library, Scopus, and Web of Science identified eligible studies. Retrospective and prospective studies comparing prophylactic pegfilgrastim with placebo or no G-CSF in patients undergoing DCF therapy were included. Eight reviewers independently screened studies, extracted data, and assessed quality using the Newcastle-Ottawa Scale. The extracted data were then verified by two additional reviewers. A meta-analysis was conducted to calculate pooled effect sizes.ResultsPooled analysis showed that <b>pegfilgrastim significantly reduced FN incidence</b> (OR = <b>0.283</b>, 95% CI: <b>0.102-0.782</b>, <b>p</b> <b>=</b> <b>0.015</b>). FN rates ranged from <b>3.3% to 30.8%</b> in the pegfilgrastim group versus <b>26.7% to 60.6%</b> in the control group. Pegfilgrastim was also associated with <b>lower rates of severe neutropenia and shorter hospital stays</b>, with no significant increase in adverse events.ConclusionsIn our study, Pegfilgrastim prophylaxis significantly reduces FN risk, severe neutropenia, and hospital stays in esophageal cancer patients receiving DCF chemotherapy, without increasing major complications. These findings support its routine use in this population, though further prospective randomized trials are needed to optimize dosing strategies and confirm long-term benefits.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1370-1379"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy of palonosetron and ondansetron for chemotherapy-induced nausea and vomiting in pediatric and adult populations: A systematic review and meta-analysis of randomized controlled trials.","authors":"Branham Bright, Abimuthra Vivekanandan, Lavanya Ayyasamy, Madhumitha Haridoss","doi":"10.1177/10781552261492619","DOIUrl":"https://doi.org/10.1177/10781552261492619","url":null,"abstract":"<p><p>AimThis systematic review and meta-analysis evaluated the efficacy and safety of palonosetron versus ondansetron for CINV prevention.MethodsA systematic review and meta-analysis of randomized controlled trials comparing palonosetron and ondansetron in patients receiving chemotherapy was conducted. PubMed, Embase, Scopus, and Cochrane CENTRAL were searched until October 2025. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane ROB 2 tool. Primary outcome was complete response in acute (0-24 h), delayed (24-120 h), and overall (0-120 h) phases. Secondary outcomes included complete control, adverse events, nausea control, rescue medication use, and emetic episodes. Random-effects models were applied, and evidence certainty was assessed using GRADE. This review was registered in PROSPERO (CRD420251172577).ResultsAmong 11 included studies, all were eligible for meta-analysis. Palonosetron showed higher pooled complete response rates than ondansetron in the acute (RR 1.06; 95% CI 1.02 to 1.11), delayed (RR 1.30; 95% CI 1.17 to 1.43), and overall phases (RR 1.29; 95% CI 1.17 to 1.42). Pooled complete control rates showed improvements mainly in the delayed phase. No significant differences were found in pooled adverse event rates, headache, constipation, rescue medication use, or emetic episodes. Sensitivity analyses confirmed stability of pooled estimates; subgroup analyses showed consistent effects across populations and chemotherapy types. Heterogeneity was low, and certainty of evidence ranged from moderate to high.ConclusionsPalonosetron demonstrates superior pooled complete response rates compared with ondansetron across all phases, with particularly significant improvements in delayed-phase control response, and a comparable safety profile.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261492619"},"PeriodicalIF":1.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safe and effective rechallenge of zanubrutinib in combination with obinutumumab in follicular lymphoma after severe drug-induced liver injury.","authors":"Hung Chang","doi":"10.1177/10781552261491648","DOIUrl":"https://doi.org/10.1177/10781552261491648","url":null,"abstract":"<p><p>IntroductionSevere liver injury is uncommonly encountered in zanubrutinib and other bruton tyrosine kinase inhibitors. In previous reports of severe liver toxicity associated with bruton kinase inhibitors, the offending agents were often withdrawn although resumption of ibrutinib was ever reported.Case ReportWe shared our clinical experience of 2 cases of follicular lymphoma treated with obinutumumab and zanubrutinib. Severe liver injury, as shown by high levels of transaminase (ALT up to 1350 and 406 IU/L respectively) occurred within a week of drug exposure.Management and OutcomeZanubrutinib was withdrawn shortly then resumed with low dose (80 mg) after hepatic enzyme levels stablized. The dose was titrated up to full dose (320 mg) and lymphoma responded well (partial response in one and complete response in the other) to treatment.ConclusionThis report highlighted a rare but important complication of zanubrutinib. On the other hand, it also suggests zanubrutinb should not be excluded from subsequent treatment and can be re-introduced with caution.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261491648"},"PeriodicalIF":1.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and safety of 30-minute Trastuzumab reloading infusion in patients with HER2-positive solid tumors.","authors":"Shemroy McCarthy, Mohammad Harris Jalili, Sara S Kim","doi":"10.1177/10781552261491928","DOIUrl":"https://doi.org/10.1177/10781552261491928","url":null,"abstract":"<p><p>IntroductionTrastuzumab is a humanized HER2 targeting monoclonal antibody, and it is indicated for the treatment of various HER-2-positive cancers, including breast and gastrointestinal cancers. The standard protocol involves a 90-min intravenous loading dose, followed by 30-min maintenance infusions. If a maintenance dose is missed by more than a week, the prescribing information recommends a 90-min reloading infusion of 8 mg/kg, regardless of prior tolerance and duration of maintenance therapies. This study aims to assess the safety of 30-min reloading infusions which has not been previously studied.MethodsThis was a single-center, retrospective cohort study that compared the safety of trastuzumab reloading 8 mg/kg as 30 min infusion and 90 min infusion in adults with HER2-positive cancers at a comprehensive cancer center. The primary endpoint was the incidence of infusion-related reactions (IRRs). Secondary endpoints included IRR severity, number of symptoms, time to reaction, rate of decrease in left ventricular ejection fraction (LVEF), and IRR risk factor identification.ResultsA total of 169 patients were included (90-min = 123; 30-min = 46). Our findings demonstrated that the shorter 30 min infusion is as safe as 90 min infusion. The IRR rate was 0% in 30 min vs. 4% in 90 min. Additionally, the mean percentage of LVEF reduction was similar between the two cohorts (4.1% in 30 min vs. 3.97% in 90 min; P = 0.99).ConclusionsTrastuzumab reloading doses can be safely administered as a 30-min infusion, without increased risk of IRR or cardiotoxicity.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261491928"},"PeriodicalIF":1.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149061870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of adverse drug reactions with medication adherence among patients with breast cancer: A systematic review and meta-analysis.","authors":"Kuan-Han Lin, Kuan-Yin Lin","doi":"10.1177/10781552261487600","DOIUrl":"https://doi.org/10.1177/10781552261487600","url":null,"abstract":"<p><p>IntroductionThis study aimed to systematically evaluate the association between adverse drug reactions, medication adherence, and outpatient treatment outcomes among women with breast cancer receiving oral anticancer therapies.MethodsA systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and guided by the Joanna Briggs Institute methodology. A comprehensive literature search was performed in PubMed, CINAHL Ultimate, Embase, MEDLINE, and Scopus to identify quantitative observational studies published in English from database inception through June 2026. Eligible studies examined the association between adverse drug reactions and medication adherence and/or outpatient treatment outcomes in female patients with breast cancer receiving oral anticancer therapies. Cohort, case-control, and cross-sectional studies conducted in outpatient settings were included. Two independent reviewers screened studies, extracted data, and assessed methodological quality using Joanna Briggs Institute critical appraisal tools. Meta-analyses were conducted when sufficient clinical and methodological homogeneity was present.ResultsForty studies involving 44,455 women were included; all evaluated oral endocrine therapy. Adverse drug reactions were associated with lower medication adherence, although substantial between-study heterogeneity limited confidence in the magnitude and generalizability of the pooled association. Evidence linking adverse drug reactions with outpatient treatment outcomes, including disease-free survival, was limited and heterogeneous, with no consistent association identified.ConclusionsAdverse drug reactions were associated with medication nonadherence among women receiving oral endocrine therapy. However, the very high heterogeneity of the adherence synthesis and the observational nature of the included studies preclude a precise common-effect or causal interpretation.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261487600"},"PeriodicalIF":1.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and financial analysis of outpatient HyperCVAD arm A administration for acute lymphoblastic leukemia.","authors":"Yujiao Sun, Ariel Dixon, Katherine Tobon, Rebecca Nelson, Amber Lubas, Bijal Shah, Timothy Kubal, Jad Chahoud, Chris Salamanca, Leidy Isenalumhe","doi":"10.1177/10781552261483170","DOIUrl":"https://doi.org/10.1177/10781552261483170","url":null,"abstract":"<p><p>IntroductionOur institution transitioned the administration of hyperCVAD arm A to the outpatient setting via an Inpatient/Outpatient (IPOP) program. This study aims to evaluate the safety and financial impact of administering hyperCVAD arm A in the outpatient setting.DesignRetrospective chart review was conducted on adult patients who received hyperCVAD arm A for treatment of ALL at our institution between January 2019 and July 2020. The primary endpoint of the study is incidence of hospital admissions during outpatient administration of hyperCVAD during arms 2A, 3A, and 4A. Secondary endpoints include hospitalizations between cycles, hospital days saved, infectious complications, adherence to infection prophylaxis guidelines, and drug-related adverse events. Financial analysis was conducted based on reimbursement data and impact of hospital bed backfill to determine the overall financial impact.ResultsA total of 103 cycles of hyperCVAD arm A were administered, with 56 cycles given outpatient to 26 patients. One (4%) patient required hospitalization during outpatient chemotherapy administration, while 8 (31%) patients were hospitalized after completing day 4 of each cycle for reasons not directly related to treatment. Grade >3 hematologic adverse events were prevalent, but no patients were removed from the program due to adverse effects. The utilization of the outpatient program resulted in an estimated 280 avoided hospitalization days during the study period and 60% increase in margin based on reimbursement.ConclusionOutpatient administration of hyperCVAD arm A was safe and feasible, with minimal hospitalizations occurring during treatment cycles. The outpatient approach demonstrated favorable financial implications and alleviated bed shortages.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261483170"},"PeriodicalIF":1.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems.","authors":"Fuxiang Wang, Hongqian Jiang, Yan Chen, Zhe Zhang, Zhen Wang, Wei Liu, Fusheng Chi","doi":"10.1177/10781552261488860","DOIUrl":"https://doi.org/10.1177/10781552261488860","url":null,"abstract":"<p><p>ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including \"EGFR-mutant NSCLC,\" \"EGFR-TKIs,\" \"drug resistance,\" \"artificial intelligence,\" and \"precision oncology.\" Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup). We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks. Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment. Continued collaborative efforts are warranted to refine treatment sequencing and translate emerging technologies into measurable patient benefit.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261488860"},"PeriodicalIF":1.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149017251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions and information needs regarding household exposure to anticancer drugs among family members living with patients receiving outpatient chemotherapy in Japan: A qualitative descriptive study.","authors":"Maho Miyazawa, Toshiaki Nakayama, Keiko Kishimoto","doi":"10.1177/10781552261485533","DOIUrl":"https://doi.org/10.1177/10781552261485533","url":null,"abstract":"<p><p>IntroductionAs outpatient chemotherapy has become increasingly common, family members may be exposed to anticancer drugs in daily life through contact with patients' body fluids and contaminated environments. However, little is known in Japan about family members' perceptions of household exposure to anticancer drugs. In this study, we explored family members' perceptions of household exposure to anticancer drugs and their information needs.MethodsSemi-structured interviews were conducted with six cohabiting family members of patients receiving outpatient cytotoxic anticancer drug therapy. The data were analyzed using a qualitative descriptive approach.ResultsSeven categories were identified and integrated into a storyline. Family members had an incomplete understanding of household exposure to anticancer drugs and expressed concerns about its potential effects on themselves and other family members. Some questioned the risks of such exposure, and all participants prioritized the patient's treatment and expressed a willingness to follow recommended preventive measures if provided with information about exposure. Perceptions of exposure risks differed according to family composition, and participants wanted information about currently available knowledge, potential risks, and preventive measures despite the limited evidence regarding household exposure.ConclusionsThese exploratory findings suggest that healthcare professionals should provide information about household exposure to anticancer drugs not only to patients but also to family members living with them, even when evidence is limited. Information provision could be tailored to individual family circumstances because perceptions of exposure risks may differ according to family composition.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261485533"},"PeriodicalIF":1.3,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors associated with survival in patients with colorectal cancer treated with capecitabine: A cohort study.","authors":"Ariela Dutra Norberto de Oliveira, Patricia Kaiser Pedroso Cava, Vanessa Cristiane da Silva Ferreira, Camille Nigri Cursino, Jessica Pronestino de Lima Moreira, Thaísa Nogueira, Dulce Helena Nunes Couto, Sabrina Calil-Elias","doi":"10.1177/10781552261487365","DOIUrl":"https://doi.org/10.1177/10781552261487365","url":null,"abstract":"<p><p><b>Introduction:</b> Colorectal cancer is a major public health problem due to its high incidence and mortality rates worldwide. Various clinical and sociodemographic characteristics are intrinsically linked to this neoplasm and can have a significant influence on both survival estimates and the utilization of healthcare resources. Within this context, capecitabine has emerged as an oral antineoplastic agent used in the treatment of this type of cancer. <b>Objective:</b> The objective of this study was to evaluate the survival of patients diagnosed with colorectal cancer who initiated treatment with capecitabine. <b>Method:</b> This is a retrospective cohort study conducted at a cancer reference center in Rio de Janeiro, Brazil, based on data collected from medical records of patients treated between 2017 and 2019. Survival analysis was performed using the Kaplan-Meier method, and the Cox proportional hazards model was used to estimate hazard ratios (HRs). <b>Results:</b> For clinical progression-free survival (cPFS), the estimated event-free probability at 12 months was 72%, while for overall survival (OS) it was 83%. Staging and performance status were associated with a higher probability of death. For both cPFS and OS, stage IV disease was associated with an approximately 3-fold increase in risk, and poor performance status with an approximately 3-fold increase for cPFS and 4-fold for OS. <b>Conclusion:</b> The results obtained reinforce the importance of individualized assessments that consider clinical and functional parameters to define the most appropriate therapeutic strategy in patients selected for a capecitabine-containing regimen.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261487365"},"PeriodicalIF":1.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}